We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Fujirebio and Sysmex to Collaborate On Development of Unique Immunoassays

By LabMedica International staff writers
Posted on 11 Oct 2023

Fujirebio Holdings (Tokyo, Japan) and Sysmex Corporation (Kobe, Japan) have entered into an agreement to expand their existing partnership across various areas, such as research, manufacturing, clinical development, and sales and marketing, in the field of immunoassay tests. More...

Sysmex has been a key player in the field of in vitro diagnostics for over half a century, establishing both a solid technological base and an expansive global network. The company is keen to accelerate its presence in the immunochemistry sector, especially in the U.S. and European markets. Sysmex has been actively working on introducing unique, value-added tests, including the development of reagents that can detect the buildup of amyloid beta (Aβ) in the brain from blood samples, a key factor in Alzheimer's disease, in both Japanese and U.S. laboratory developed test (LDT) markets.

Fujirebio, on the other hand, boasts a comprehensive portfolio of reagent raw materials due to its long history in the immunoassay field. Lately, the company has not only been focused on developing its own products but has also been strengthening its Contract Development and Manufacturing Organization (CDMO) strategy to promote the global roll-out of specialized tests. Since 2020, Fujirebio has been collaborating with Sysmex by creating specialized reagents for Sysmex's Automated Immunoassay System, known as HISCL-Series, through its subsidiary companies.

Both Fujirebio and Sysmex have agreed to further deepen their cooperative efforts. This decision is based on a mutual understanding that pooling their individual expertise in the immunoassay field can help them both expand globally and foster advances in this scientific area. The companies plan to identify specific areas where they can collaborate more deeply—like research, manufacturing, clinical trials, and sales strategies—with the goal of moving to the implementation stage by the end of March 2024. Fujirebio and Sysmex are committed to offering high-value tests to their global customer base as early as possible, driven by the strengthening of their partnership in immunoassay.

Related Links:
Fujirebio Holdings 
Sysmex Corporation 


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.